Celldex Therapeutics Inc (CLDX) — Strategic Asset Allocation Index
Celldex Therapeutics Inc (CLDX) has a Strategic Asset Allocation Index of 1.4% as of June 2023. Strategic assets (PP&E of $3.94 Million plus long-term investments of $-) total $3.94 Million, measured against net assets of $277.54 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Celldex Therapeutics Inc Strategic Asset Allocation Index (2005–2022)
This chart shows how Celldex Therapeutics Inc's Strategic Asset Allocation Index has evolved across 17 annual periods from 2005 to 2022. As of June 2023, the index stands at 1.4%, representing strategic assets of $3.94 Million against net assets of $277.54 Million USD. Explore CLDX cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Celldex Therapeutics Inc (2005–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Celldex Therapeutics Inc from 2005 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see CLDX stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 2.4% | $7.75 Million | $7.75 Million | $- | $326.20 Million | ▲ +0.8 pp |
| 2021 | 1.6% | $6.52 Million | $6.52 Million | $- | $419.48 Million | ▼ -1.9 pp |
| 2020 | 3.5% | $7.26 Million | $7.26 Million | $- | $209.36 Million | ▼ -0.8 pp |
| 2019 | 4.3% | $4.03 Million | $4.03 Million | $- | $94.03 Million | ▼ -2.1 pp |
| 2018 | 6.4% | $7.91 Million | $6.11 Million | $1.80 Million | $124.06 Million | ▲ +1.2 pp |
| 2017 | 5.1% | $12.17 Million | $10.37 Million | $1.80 Million | $236.37 Million | ▲ +0.2 pp |
| 2016 | 5.0% | $13.19 Million | $13.19 Million | $- | $265.43 Million | ▲ +1.0 pp |
| 2015 | 4.0% | $11.46 Million | $11.46 Million | $- | $290.11 Million | ▼ -1.0 pp |
| 2014 | 5.0% | $10.54 Million | $10.54 Million | $- | $211.66 Million | ▲ +1.9 pp |
| 2013 | 3.1% | $9.97 Million | $9.97 Million | $- | $319.80 Million | ▼ -4.4 pp |
| 2012 | 7.5% | $7.21 Million | $7.21 Million | $- | $95.77 Million | ▼ -5.7 pp |
| 2011 | 13.2% | $9.09 Million | $9.09 Million | $- | $68.72 Million | ▼ -1.2 pp |
| 2010 | 14.4% | $10.83 Million | $10.83 Million | $- | $75.25 Million | ▼ -1.2 pp |
| 2009 | 15.6% | $11.49 Million | $11.49 Million | $- | $73.77 Million | ▼ -59.2 pp |
| 2008 | 74.8% | $13.57 Million | $13.57 Million | $- | $18.13 Million | ▼ -43.3 pp |
| 2006 | 118.1% | $2.55 Million | $2.55 Million | $- | $2.16 Million | ▲ +105.2 pp |
| 2005 | 13.0% | $2.71 Million | $2.71 Million | $- | $20.89 Million | — |